NEW YORK—An investigational triple regimen of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) may result in significantly greater mean reductions in BP compared ...
The researchers found that the proportion of patients achieving target BP was increased with the triple combination pill versus usual care at 6 months (70 vs 55%; risk difference, 12.7%). HealthDay ...
Patients who mix a diuretic and renin-angiotensin system (RAS) inhibitor with a nonsteroidal anti-inflammatory drug (NSAID) could face a higher risk of developing acute kidney injury (AKI), a new ...
Proportion achieving target BP increased with use of triple combo pill versus usual care at six months. TUESDAY, Aug. 14, 2018 (HealthDay News) — Treatment with a pill combining low doses of 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback